The hidden burden of atopic dermatitis in central and Eastern European countries.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-16 DOI:10.1080/14737167.2024.2416249

Baher Elezbawy, Zoltán Kaló, Ahmad Fasseeh, András Inotai, Bertalan Nemeth, Tamás Ágh

{"title":"The hidden burden of atopic dermatitis in central and Eastern European countries.","authors":"Baher Elezbawy, Zoltán Kaló, Ahmad Fasseeh, András Inotai, Bertalan Nemeth, Tamás Ágh","doi":"10.1080/14737167.2024.2416249","DOIUrl":null,"url":null,"abstract":"Background: Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries.Methods: We created a burden of disease model to quantify AD's hidden burden. Humanistic burden was calculated by estimating the monetary value of quality-adjusted life years (QALYs) lost, using prevalence data from the Global Burden of Disease study and gross domestic product (GDP) per capita for each country. Indirect economic burden was estimated based on productivity loss from absenteeism and presenteeism, adjusted for labor force participation and unemployment rates. Total hidden burden was determined by combining productivity losses and QALYs lost.Results: QALY loss due to AD ranged from 1,832 to 58,596 annually in CEE countries, equating to 38 million to approximately 1 billion Euros per country. Productivity losses ranged from 3.6 to 148.9 million Euros annually. The total hidden burden of AD represents 0.11% to 0.43% of the GDP.Conclusions: Our estimates reflect significant differences in population size, prevalence, and economic strength among CEE countries. Adjusting findings to country-specific GDP provided insights into AD's true hidden burden, offering valuable information for decision-making.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2416249","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries.

Methods: We created a burden of disease model to quantify AD's hidden burden. Humanistic burden was calculated by estimating the monetary value of quality-adjusted life years (QALYs) lost, using prevalence data from the Global Burden of Disease study and gross domestic product (GDP) per capita for each country. Indirect economic burden was estimated based on productivity loss from absenteeism and presenteeism, adjusted for labor force participation and unemployment rates. Total hidden burden was determined by combining productivity losses and QALYs lost.

Results: QALY loss due to AD ranged from 1,832 to 58,596 annually in CEE countries, equating to 38 million to approximately 1 billion Euros per country. Productivity losses ranged from 3.6 to 148.9 million Euros annually. The total hidden burden of AD represents 0.11% to 0.43% of the GDP.

Conclusions: Our estimates reflect significant differences in population size, prevalence, and economic strength among CEE countries. Adjusting findings to country-specific GDP provided insights into AD's true hidden burden, offering valuable information for decision-making.

查看原文本刊更多论文

中欧和东欧国家特应性皮炎的隐性负担。

背景：特应性皮炎（AD）对生活质量和生产率造成负面影响，从而带来隐性负担。我们旨在估算中东欧（CEE）国家成人和青少年的隐性负担：方法：我们创建了一个疾病负担模型来量化注意力缺失症的隐性负担。人文负担是通过估算质量调整生命年（QALYs）损失的货币价值来计算的，使用的是全球疾病负担研究（Global Burden of Disease study）的患病率数据和每个国家的人均国内生产总值（GDP）。间接经济负担是根据缺勤和旷工造成的生产力损失估算的，并根据劳动力参与率和失业率进行了调整。总的隐性负担由生产率损失和 QALYs 损失共同决定：中欧和东欧国家每年因急性营养不良造成的 QALY 损失从 1,832 到 58,596 不等，相当于每个国家 3800 万到约 10 亿欧元。生产力损失每年从 360 万欧元到 1.489 亿欧元不等。急性肠梗阻的隐性总负担占国内生产总值的 0.11% 至 0.43%：我们的估计结果反映了中欧和东欧国家在人口规模、发病率和经济实力方面的显著差异。根据具体国家的 GDP 对研究结果进行调整后，我们可以深入了解急性肠梗阻的真正隐性负担，为决策提供有价值的信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.